Beijing Immunochina Pharmaceutical Closes Series C+ at CNY 100 Mn
Immunochina Pharmaceutical announced today that they closed the Series C+ at an amount of CNY 100 million. The fund raised will support the research development of new oncology therapy products and marketing roll-out.
Established in 2015, the company focuses on the new generation of CAR-T technology to achieve full-process serum-free production, large-scale gene vector preparation, high production success rate and long-term persistence of CAR-T cells.
At the beginning of 2019, Immunochina raised CNY 140 million from Sherpa VC, Huarun Innovation PE, Qingze Investment, Shougang Fund and Peter Thiel. It was already two years after the company received bankroll in Series B in 2017 – at CNY 50 million.